Active clinical trials for "Diabetes Mellitus, Type 2"

Following the 6th Tromso study subjects with HbA1c > 5.7 plus a subsample of subjects with lower hba1c values will be invited to an oral glucose tolerance test to see the predictive value of HBA1c in the diagnosis of type 2 diabetes.

This study will investigate the effects of gastric bypass surgery on type II diabetes. The study will recruit patients with type II diabetes having Roux-en-Y gastric bypass, patients without type II diabetes having Roux-en-Y gastric bypass, and control subjects (patients having gastroscopy, but no surgery). Targeted enrollment is 30 patients per group. Samples of intestine are taken prior to surgery in gastroscopy, during surgery, and 6 months after surgery during gastroscopy. Meal test with incretin measurements, and feces and blood samplings are performed before and after surgery Hypotheses are: The pathogenesis of type II diabetes is linked to changes in the expression of intestinal endocrine cells The changes in the incretine excretion after the gastric bypass surgery partly explain the amelioration of type II diabetes The oxidation of lipoprotein is diminished after the gastric bypass surgery slowing the development of atherosclerosis The immunologic functions of the intestine are changed by the gastric bypass surgery attenuating systemic inflammation The gastric bypass surgery changes cholesterol and bile acid metabolism The gastric bypass surgery changes the fecal microbiota Primary end points are: Changes in the amounts of endocrine cells in ventricle, duodenum and jejunum Changes in the incretine secretion studied with liquid meal test Changes in the oxidation of lipoproteins Changes in the immunologic markers in ventricle, duodenum and jejunum Changes in the amounts of phytosterols, cholesterol metabolites and bile acids Changes in fecal microbiota

This study is conducted in Japan. The aim of this study is to collect data of production of insulin aspart specific antibody under normal clinical practice conditions.

This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.

This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).

The purpose of this study is to demonstrate the performance of the Enlite Sensor over an entire calibration and wear period of 146 hours (6 days) when inserted in the abdomen and buttock and used with the Revel 2.0 Pumps in subjects age 18 - 75 years.

This study is conducted in Asia. The aim of of this study is to evaluate the safety of NovoPen® 3 and/or FlexPen® devices (if available on the market) measured by the number of adverse events and technical complaints in patients with type 1 and type 2 diabetes in routine clinical practice.

The data from this study will be used to compare the kinetic profile of metformin 500mg in linagliptin/metformin fixed dose combination tablet versus Canadian metformin reference product administered concomitantly with linagliptin 2.5 mg tablet.

This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using insulin aspart in children with diabetes under normal clinical practice conditions.

This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia under normal clinical practice.